GSK’s dabrafenib to be available on the NHS?
By Aine Slowey, Lead Analyst
18 September 2014
I am the Lead Analyst for cardiovascular and metabolic diseases at Datamonitor Healthcare. I have a DPhil in Organic Che...
Read full bio
Áine Slowey, senior analyst at Datamonitor Healthcare says:
“Our forecasts predict that 11,600 people in the UK will be diagnosed with melanoma in 2014. This increases to 11,800 in 2015, and to 13,190 by 2022. Dabrafenib’s availability on the NHS would provide another treatment option for patients, alongside the existing treatment Zelboraf (vemurafenib; Roche).
“The drug has also demonstrated clinical activity in melanoma that has spread to the brain. This is very promising, as before dabrafenib’s approval, the off-label use of Temodar (temozolomide; Merck & Co) was the only treatment option available to these patients.
“We expect dabrafenib to generate sales of $29m in the UK and total sales of $265m in the US and five major EU markets by 2022.”
“It is the combination of dabrafenib and GlaxoSmithKline’s MEK inhibitor Mekinist (trametinib) that is likely to become the preferable treatment option for BRAF mutation-positive melanoma patients, as these drugs act on complementary cellular pathways and overcome some of the problems associated with drug resistance.
With GSK’s trametinib monotherapy gaining EU approval in July 2014, NICE may now face pressure to accelerate its assessment of trametinib, so that both it and dabrafenib may potentially be made available on the NHS. This would allow for rapid uptake of both drugs in combination with each other once the combination therapy is approved for use in the EU.”
Posted in Oncology.